[go: up one dir, main page]

WO2022218973A3 - Pyrrolobenzodiazepine conjugates - Google Patents

Pyrrolobenzodiazepine conjugates Download PDF

Info

Publication number
WO2022218973A3
WO2022218973A3 PCT/EP2022/059733 EP2022059733W WO2022218973A3 WO 2022218973 A3 WO2022218973 A3 WO 2022218973A3 EP 2022059733 W EP2022059733 W EP 2022059733W WO 2022218973 A3 WO2022218973 A3 WO 2022218973A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolobenzodiazepine conjugates
pyrrolobenzodiazepine
conjugates
group
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/059733
Other languages
French (fr)
Other versions
WO2022218973A2 (en
Inventor
Philip Wilson Howard
Luke Masterson
Arnaud Charles Tiberghien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of WO2022218973A2 publication Critical patent/WO2022218973A2/en
Publication of WO2022218973A3 publication Critical patent/WO2022218973A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain; D represents either group D1 or D2. D' represents either group D'1 or D'2.
PCT/EP2022/059733 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates Ceased WO2022218973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2105186.7A GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates
GB2105186.7 2021-04-12

Publications (2)

Publication Number Publication Date
WO2022218973A2 WO2022218973A2 (en) 2022-10-20
WO2022218973A3 true WO2022218973A3 (en) 2022-12-22

Family

ID=75949544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/059733 Ceased WO2022218973A2 (en) 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates

Country Status (4)

Country Link
AR (1) AR125338A1 (en)
GB (1) GB202105186D0 (en)
TW (1) TW202308697A (en)
WO (1) WO2022218973A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018069490A1 (en) * 2016-10-14 2018-04-19 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019034764A1 (en) * 2017-08-18 2019-02-21 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019224340A1 (en) * 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020006722A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
WO2020073345A1 (en) * 2018-10-12 2020-04-16 Hangzhou Dac Biotech Co., Ltd Conjugation linkers containing 2,3-diaminosuccinyl group
GB2581394A (en) * 2019-02-18 2020-08-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (en) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd Antibiotic DC-81 and its manufacturing method
ES2398975T3 (en) 2004-03-01 2013-03-25 Spirogen Sàrl 11-Hydroxy-5H-pyrrolo [2,1-c] [1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
SI1879901T1 (en) 2005-04-21 2010-04-30 Spirogen Ltd Pyrrolobenzodiazepines
DK1813614T3 (en) 2006-01-25 2012-01-23 Sanofi Sa Cytotoxic agents comprising novel tomaymycin derivatives
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
BR112012026213B1 (en) 2010-04-15 2021-12-28 Medimmune Limited PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE
JP6014596B2 (en) 2010-11-09 2016-10-25 メディミューン，エルエルシー Antibody scaffold for homogeneous conjugation
KR101412875B1 (en) 2012-10-04 2014-07-02 삼성전기주식회사 Gate driving circuit and inverter having the same
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP6307519B2 (en) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
RS58440B1 (en) 2014-04-11 2019-04-30 Medimmune Llc Conjugated compounds comprising cysteine-engineered antibodies
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
KR20190083654A (en) 2016-11-10 2019-07-12 메디뮨 엘엘씨 Binding molecules specific for ASCT2 and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018069490A1 (en) * 2016-10-14 2018-04-19 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019034764A1 (en) * 2017-08-18 2019-02-21 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019224340A1 (en) * 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020006722A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
WO2020073345A1 (en) * 2018-10-12 2020-04-16 Hangzhou Dac Biotech Co., Ltd Conjugation linkers containing 2,3-diaminosuccinyl group
GB2581394A (en) * 2019-02-18 2020-08-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
WO2022218973A2 (en) 2022-10-20
GB202105186D0 (en) 2021-05-26
TW202308697A (en) 2023-03-01
AR125338A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
CO2023016939A2 (en) Exatecan derivatives and their antibody-drug conjugates
PE20220764A1 (en) ANTIBODY AND DRUG CONJUGATES
ATE247128T1 (en) AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
MX2023011563A (en) ANTI-NECTIN-4 ANTIBODY AND EXATECANE CONJUGATES.
DE50210328D1 (en) BIS SPECIFIC ANTI-CD28 ANTIBODY MOLECULE
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
DK1492526T3 (en) Conjugated prodrugs of CC-1065 analogs
DE122006000004I1 (en) Fungicides Tetrahydrofurans
DK0693132T3 (en) Rapamycinassay
DE69932733D1 (en) PHOTOSENSITIZER CONJUGATES FOR TARGETING INTRA-CELLULAR PATHOGENES
PT753301E (en) COMBINATION OF A BENZIMIDAZOLE HAVING ACTIVITY ANTAGONISTA OF ANGIOTENSINA II WITH A DIURETIC
MX2024014939A (en) MULTIDRUG ANTIBODY CONJUGATE
AU2002303181A1 (en) Morpholino imaging and therapy
CY1112246T1 (en) PASTALOSANIDA IN DOUBLE-T SHAPE
DK1327146T3 (en) Compound with a branched linker molecule
FI4217398T3 (en) C-MET ANTIBODY-DRUG CONJUGATES
WO2022218973A3 (en) Pyrrolobenzodiazepine conjugates
MX2024015179A (en) Antibody drug conjugates
MX2022008437A (en) Site specific antibody-drug conjugates with peptide-containing linkers.
DE60324664D1 (en) ANTI-CCR5 ANTIBODY
MX2025005811A (en) Ceacam5 antibody-drug conjugates and methods of use thereof
ATE146081T1 (en) CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
MX2022013298A (en) CONJUGATES OF DRUG ANTIBODIES.
MX2025012144A (en) Targeted pyrrolobenzodiazapine conjugates
MX2025004585A (en) Antibodies, antibody-drug conjugates, preparations and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22722262

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22722262

Country of ref document: EP

Kind code of ref document: A2